Suppr超能文献

西黄丸联合化疗对晚期结直肠癌患者的临床疗效

Clinical Effects of Xihuang Pill Combined with Chemotherapy in Patients with Advanced Colorectal Cancer.

作者信息

Yu Dan, An Guang Yu

机构信息

Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

出版信息

Evid Based Complement Alternat Med. 2017;2017:5936086. doi: 10.1155/2017/5936086. Epub 2017 Mar 28.

Abstract

. To investigate the therapeutic effects of Xihuang pill combined with chemotherapy on advanced colorectal cancer. Sixty-three patients with advanced colorectal cancer were divided into an experimental group ( = 32) and control group ( = 31). Patients in the experimental group were treated with traditional Chinese medicine combined with Western medicine (i.e., Xihuang pill with FOLFOX or FOLFIRI chemotherapy), and those in the control group were treated with FOLFOX or FOLFIRI chemotherapy alone. Changes in therapeutic efficacy, side effects, blood coagulation function, and quality of life (QOL) were compared between the two groups. . The response rate was higher in the experimental than control group ( = 0.011). The QOL score in the experimental group was significantly lower after treatment than before treatment ( = 0.003), while no significant change was found in the control group. In the experimental group, the posttreatment activated partial thromboplastin time and prothrombin time after treatment were 30.05 ± 3.85 and 10.40 ± 1.25 s, respectively, which were prolonged compared with those before treatment (29.12 ± 4.03 and 9.85 ± 1.00 s; = 0.010 and 0.021, respectively). . In patients with advanced colorectal cancer, Xihuang pill combined with chemotherapy can significantly enhance the therapeutic effects compared with chemotherapy alone and improve patients' QOL and hypercoagulability.

摘要

观察西黄丸联合化疗治疗晚期结直肠癌的疗效。将63例晚期结直肠癌患者分为实验组(n = 32)和对照组(n = 31)。实验组患者采用中西医结合治疗(即西黄丸联合FOLFOX或FOLFIRI化疗),对照组患者仅采用FOLFOX或FOLFIRI化疗。比较两组患者的治疗效果、副作用、凝血功能及生活质量(QOL)的变化。实验组的缓解率高于对照组(P = 0.011)。实验组治疗后的QOL评分显著低于治疗前(P = 0.003),而对照组未发现显著变化。实验组治疗后活化部分凝血活酶时间和凝血酶原时间分别为30.05±3.85和10.40±1.25秒,与治疗前相比延长(分别为29.12±4.03和9.85±1.00秒;P分别为0.010和0.021)。对于晚期结直肠癌患者,西黄丸联合化疗与单纯化疗相比可显著提高治疗效果,并改善患者的QOL及高凝状态。

相似文献

3
The prospect of pill in the treatment of cancers.药丸用于癌症治疗的前景。
Heliyon. 2023 Apr 14;9(4):e15490. doi: 10.1016/j.heliyon.2023.e15490. eCollection 2023 Apr.
9
Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer.西黄丸联合化疗治疗乳腺癌疗效的Meta分析
Evid Based Complement Alternat Med. 2019 Mar 12;2019:3502460. doi: 10.1155/2019/3502460. eCollection 2019.

引用本文的文献

6
The prospect of pill in the treatment of cancers.药丸用于癌症治疗的前景。
Heliyon. 2023 Apr 14;9(4):e15490. doi: 10.1016/j.heliyon.2023.e15490. eCollection 2023 Apr.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验